In comments on the Centers for Medicare & Medicaid Services' advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs, AHA commends the agency's willingness to address excessive growth in drug prices, but "given the amount of model specifics still to be determined, the anticipated operational burdens, as well as other logistical concerns, the AHA urges CMS to consider narrowing the scope of the program to a more targeted intervention than that described in the ANPRM." AHA's Dec. 27 comments and concerns focused on the ANPRM's impact on hospitals participating in the 340B Drug Pricing Program; regulatory and operational burden; payment reductions; and model vendors' fees and policies. The AHA noted that its primary concern is the model's interaction with the 340B program and asked CMS to hold 340B hospitals harmless under the model. AHA said it looks forward to working with CMS "to improve the IPI model."

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…
Headline
A federal judge yesterday struck down a Centers for Medicare…
Headline
Drug makers this week increased list prices for at least 104 different drugs, dosages or package sizes, with the average price increase 13.1%, according to an…
Headline
The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.
Headline
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which…